Hector-Study to Evaluate the Efficacy of Octreotide in Patients With Inoperable Hepatocellular Carcinoma
Status:
Completed
Trial end date:
2003-02-01
Target enrollment:
Participant gender:
Summary
A preliminary study has shown that the hormone-similar, growth-retarding drug octreotide can
prolong survival time in patients with primary liver cancer. Due to methodological
deficiencies of the preliminary study the results will be re-checked by the comparison of
octreotide with an pseudo-drug (so-called placebo) primarily regarding to the survival time
and secondarily concerning costs, side effects, patient cooperation and quality of life as
well as specific conditions in the tumor tissue in both groups with 108 patients with primary
liver cancer.
Phase:
Phase 3
Details
Lead Sponsor:
University Hospital Freiburg
Collaborators:
Deutsche Krebshilfe e.V., Bonn (Germany) German Federal Ministry of Education and Research Novartis